retatrutide is the most under-discussed thing on this board
retatrutide is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is…
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Which phase 2 arm are you quoting, and at what week?
the TRIUMPH programme is still running, so anything definitive is premature
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
the glucagon component is why the metabolic story reads differently
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.